20 novembre 2025

Distalmotion SA, an international MedTech company based in Lausanne, successfully closed its USD 150 million Series G financing round led by Revival Healthcare Capital and including inside investor participation.

The new funding will be used primarily to accelerate US commercial adoption of DEXTER, Distalmotion’s soft tissue robotic surgery system, as well as to support ongoing clinical and product development initiatives. A major focus of the US expansion continues to be the Ambulatory Surgery Center (ASC) market—one of the fastest-growing segments in surgical care, driven by the ongoing shift toward efficient, outpatient surgery.

Walder Wyss advised Distalmotion in connection with the transaction. The team was led by Alex Nikitine (Corporate/M&A, Partner) and Dimitrios Berger (Corporate/M&A, Managing Associate) and Iliana Djagova (Corporate/M&A, Counsel), and further included Merens Derungs (Corporate/M&A, Associate), Timon Nydegger (Corporate/M&A, Managing Associate), Ken Savioz (Corporate/M&A, Senior Associate), André Kuhn (Notary, Partner), Simon Olstein (Corporate/M&A, Senior Associate), Lia Müller (Corporate/M&A, Trainee Lawyer) and Dominik Lusti (Corporate/M&A, Trainee Lawyer).